KR100367948B1 - 백혈구부착분자vla-4에대한인체화된항체 - Google Patents

백혈구부착분자vla-4에대한인체화된항체 Download PDF

Info

Publication number
KR100367948B1
KR100367948B1 KR1019960703987A KR19960703987A KR100367948B1 KR 100367948 B1 KR100367948 B1 KR 100367948B1 KR 1019960703987 A KR1019960703987 A KR 1019960703987A KR 19960703987 A KR19960703987 A KR 19960703987A KR 100367948 B1 KR100367948 B1 KR 100367948B1
Authority
KR
South Korea
Prior art keywords
sequence
variable region
humanized
amino acid
seq
Prior art date
Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
Expired - Lifetime
Application number
KR1019960703987A
Other languages
English (en)
Korean (ko)
Other versions
KR970700513A (ko
Inventor
매리 엠 벤디그
올리비에 제이 레제
조스 샐댄하
태런 에스. 존스
테드 에이 옛노크
Original Assignee
엘란 파마슈티칼스, 인크.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by 엘란 파마슈티칼스, 인크. filed Critical 엘란 파마슈티칼스, 인크.
Publication of KR970700513A publication Critical patent/KR970700513A/ko
Application granted granted Critical
Publication of KR100367948B1 publication Critical patent/KR100367948B1/ko
Assigned to 비오겐 아이덱 인터네셔널 홀딩 리미티드. reassignment 비오겐 아이덱 인터네셔널 홀딩 리미티드. 권리의 전부이전등록 Assignors: 엘란 파마슈티칼스, 인크.
Assigned to 비오겐 아이덱 엠에이 아이엔씨. reassignment 비오겐 아이덱 엠에이 아이엔씨. 권리의 전부이전등록 Assignors: 비오겐 아이덱 인터네셔널 홀딩 리미티드.
Anticipated expiration legal-status Critical
Expired - Lifetime legal-status Critical Current

Links

Classifications

    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K39/00—Medicinal preparations containing antigens or antibodies
    • A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P29/00—Non-central analgesic, antipyretic or antiinflammatory agents, e.g. antirheumatic agents; Non-steroidal antiinflammatory drugs [NSAID]
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P37/00—Drugs for immunological or allergic disorders
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P7/00—Drugs for disorders of the blood or the extracellular fluid
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K16/00—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies
    • C07K16/18—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans
    • C07K16/28—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants
    • C07K16/2839—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily
    • C07K16/2842—Immunoglobulins [IG], e.g. monoclonal or polyclonal antibodies against material from animals or humans against receptors, cell surface antigens or cell surface determinants against the integrin superfamily against integrin beta1-subunit-containing molecules, e.g. CD29, CD49
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K38/00—Medicinal preparations containing peptides
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2317/00—Immunoglobulins specific features
    • C07K2317/20—Immunoglobulins specific features characterized by taxonomic origin
    • C07K2317/24—Immunoglobulins specific features characterized by taxonomic origin containing regions, domains or residues from different species, e.g. chimeric, humanized or veneered
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07K—PEPTIDES
    • C07K2319/00—Fusion polypeptide

Landscapes

  • Health & Medical Sciences (AREA)
  • Chemical & Material Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • Organic Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Immunology (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Engineering & Computer Science (AREA)
  • Biochemistry (AREA)
  • Molecular Biology (AREA)
  • Proteomics, Peptides & Aminoacids (AREA)
  • Biophysics (AREA)
  • Genetics & Genomics (AREA)
  • Biomedical Technology (AREA)
  • Microbiology (AREA)
  • Pain & Pain Management (AREA)
  • Rheumatology (AREA)
  • Hematology (AREA)
  • Neurology (AREA)
  • Neurosurgery (AREA)
  • Diabetes (AREA)
  • Mycology (AREA)
  • Epidemiology (AREA)
  • Peptides Or Proteins (AREA)
  • Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
  • Preparation Of Compounds By Using Micro-Organisms (AREA)
  • Organic Low-Molecular-Weight Compounds And Preparation Thereof (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
KR1019960703987A 1994-01-25 1995-01-25 백혈구부착분자vla-4에대한인체화된항체 Expired - Lifetime KR100367948B1 (ko)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US18626994A 1994-01-25 1994-01-25
US08/186269 1994-01-25

Publications (2)

Publication Number Publication Date
KR970700513A KR970700513A (ko) 1997-02-12
KR100367948B1 true KR100367948B1 (ko) 2003-07-12

Family

ID=22684288

Family Applications (1)

Application Number Title Priority Date Filing Date
KR1019960703987A Expired - Lifetime KR100367948B1 (ko) 1994-01-25 1995-01-25 백혈구부착분자vla-4에대한인체화된항체

Country Status (21)

Country Link
EP (2) EP0804237B8 (enExample)
JP (5) JP4115517B2 (enExample)
KR (1) KR100367948B1 (enExample)
CN (1) CN1211123C (enExample)
AT (1) ATE333895T1 (enExample)
AU (1) AU703152B2 (enExample)
CA (1) CA2182013C (enExample)
DE (2) DE122006000043I1 (enExample)
DK (2) DK0804237T3 (enExample)
ES (2) ES2424292T3 (enExample)
FI (1) FI117509B (enExample)
FR (1) FR06C0024I2 (enExample)
HU (1) HU220799B1 (enExample)
LU (1) LU91271I2 (enExample)
MX (1) MX9602971A (enExample)
NL (1) NL300238I2 (enExample)
NO (3) NO319867B1 (enExample)
NZ (1) NZ279730A (enExample)
PL (1) PL181827B1 (enExample)
PT (1) PT804237E (enExample)
WO (1) WO1995019790A1 (enExample)

Families Citing this family (52)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US6307025B1 (en) 1989-04-28 2001-10-23 Biogen, Inc. VCAM fusion proteins and DNA coding therefor
US5871734A (en) * 1992-01-13 1999-02-16 Biogen, Inc. Treatment for asthma with VLA-4 blocking agents
US5932214A (en) 1994-08-11 1999-08-03 Biogen, Inc. Treatment for inflammatory bowel disease with VLA-4 blockers
NZ261259A (en) 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
JP3593343B2 (ja) * 1993-02-09 2004-11-24 バイオジェン インコーポレイテッド インシュリン依存型糖尿病の治療
US5840299A (en) * 1994-01-25 1998-11-24 Athena Neurosciences, Inc. Humanized antibodies against leukocyte adhesion molecule VLA-4
US7435802B2 (en) 1994-01-25 2008-10-14 Elan Pharaceuticals, Inc. Humanized anti-VLA4 immunoglobulins
US7750137B2 (en) 1995-09-01 2010-07-06 Millennium Pharmaceuticals, Inc. Mucosal vascular addressins
US6551593B1 (en) 1995-02-10 2003-04-22 Millennium Pharmaceuticals, Inc. Treatment of Inflammatory bowel disease by inhibiting binding and/or signalling through α 4 β 7 and its ligands and madcam
US7803904B2 (en) 1995-09-01 2010-09-28 Millennium Pharmaceuticals, Inc. Mucosal vascular addressing and uses thereof
US7147851B1 (en) 1996-08-15 2006-12-12 Millennium Pharmaceuticals, Inc. Humanized immunoglobulin reactive with α4β7 integrin
WO1998051345A2 (en) * 1997-05-09 1998-11-19 The John P. Robarts Research Institute Method for dislodging infiltrated leukocytes from a tissue
DE19741235A1 (de) 1997-09-18 1999-03-25 Hoechst Marion Roussel De Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19741873A1 (de) * 1997-09-23 1999-03-25 Hoechst Marion Roussel De Gmbh Neue 5-Ring-Heterocyclen, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
DE19751251A1 (de) 1997-11-19 1999-05-20 Hoechst Marion Roussel De Gmbh Substituierte Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmezeutische Präparate
DE19821483A1 (de) 1998-05-14 1999-11-18 Hoechst Marion Roussel De Gmbh Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
AU757873B2 (en) * 1998-09-14 2003-03-06 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
US7618630B2 (en) 1998-09-14 2009-11-17 Board Of Regents, The University Of Texas System Methods of treating multiple myeloma and myeloma-induced bone resorption using integrin antagonists
PL198975B1 (pl) 1999-04-22 2008-08-29 Biogen Idec Inc Zastosowanie kompozycji zawierającej homolog przeciwciała, który jest antagonistą interakcji między integryną niosącą podjednostkę alfa 4 a jej ligandem
DE19922462A1 (de) 1999-05-17 2000-11-23 Aventis Pharma Gmbh Spiro-imidazolidinderivate, ihre Herstellung ihre Verwendung und sie enthaltende pharmazeutische Präparate
HK1043320A1 (zh) 1999-06-01 2002-09-13 Biogen, Inc. Vla-1的一种阻塞性单系抗体，以及其治疗炎性失调的功用
US6949245B1 (en) 1999-06-25 2005-09-27 Genentech, Inc. Humanized anti-ErbB2 antibodies and treatment with anti-ErbB2 antibodies
JP2003517023A (ja) * 1999-12-16 2003-05-20 バイオジェン インコーポレイテッド 中枢神経系の虚血性損傷または出血性損傷を、抗α４インテグリンアンタゴニストを用いて処置する方法
DE10111877A1 (de) 2001-03-10 2002-09-12 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung, ihre Verwendung und sie enthaltende pharmazeutische Präparate
UA83791C2 (ru) 2001-04-13 2008-08-26 Байоджен Айдек Ма Инк. Антитело против vla-1, фармацевтическая композиция, которая его содержит, и из применение для лечения индивидуума с иммунологическим расстройством, опосредованным vla-1
DE10137595A1 (de) 2001-08-01 2003-02-13 Aventis Pharma Gmbh Neue Imidazolidinderivate, ihre Herstellung und ihre Verwendung
SI1485127T1 (sl) 2002-02-25 2011-09-30 Elan Pharm Inc Dajanje aktivne snovi za zdravljenje vnetja
JP2005535572A (ja) * 2002-04-12 2005-11-24 メディミューン，インコーポレーテッド 組換え抗インターロイキン−９抗体
GB0210121D0 (en) 2002-05-02 2002-06-12 Celltech R&D Ltd Biological products
TWI323265B (en) * 2002-08-06 2010-04-11 Glaxo Group Ltd Antibodies
CN100432105C (zh) * 2002-12-17 2008-11-12 默克专利有限公司 与gd2结合的小鼠14.18抗体的人源化抗体(h14.18)以及其与il-2的融合
CU23403A1 (es) * 2003-04-23 2009-08-04 Centro Inmunologia Molecular Anticuerpos recombinantes y fragmentos que reconocen el gangliósido n-glicolil gm3 y su uso para diagnóstico y tratamiento de tumores
EP1700850B1 (en) 2003-12-22 2015-07-15 Ajinomoto Co., Inc. Phenylalanine derivative
JP2008520717A (ja) * 2004-11-19 2008-06-19 バイオジェン・アイデック・エムエイ・インコーポレイテッド 多発性硬化症についての処置
JP2009515552A (ja) * 2005-11-17 2009-04-16 ミレニアム・ファーマシューティカルズ・インコーポレイテッド α４β７インテグリン反応性ヒト化免疫グロブリン
BRPI0712607A8 (pt) 2006-05-25 2019-06-04 Biogen Idec Inc métodos de tratamento de acidente vascular cerebral
EP2510941A3 (en) 2007-02-20 2013-01-23 Merrimack Pharmaceuticals, Inc. Methods of treating multiple sclerosis by administration of alpha-fetoprotein in combination with an integrin antagonist
NZ595526A (en) * 2007-06-14 2013-03-28 Biogen Idec Inc Pharmaceutical composition comprising a vla-4 binding antibody, a phosphate buffer and a surfactant
EP2221325B1 (en) 2007-12-13 2014-04-16 Tokuyama Corporation Photochromic curable composition
BRPI0911652A2 (pt) 2008-04-11 2015-08-04 Merrimack Pharmaceuticals Inc Ligantes de albumina sérica humana e seus conjugados
WO2010107752A2 (en) 2009-03-20 2010-09-23 Amgen Inc. Alpha-4-beta-7 heterodimer specific antagonist antibody
US20120258093A1 (en) 2009-08-20 2012-10-11 Institut National De La Sante Et De La Recherche Medicale (Inserm) Vla-4 as a biomarker for prognosis and target for therapy in duchenne muscular dystrophy
EA201291065A1 (ru) 2010-04-16 2013-03-29 Байоджен Айдек Ма Инк. Антитела против vla-4
TWI907924B (zh) 2011-05-02 2025-12-11 日商武田藥品工業股份有限公司 抗-α4β7抗體之調配物
UA116189C2 (uk) 2011-05-02 2018-02-26 Мілленніум Фармасьютікалз, Інк. КОМПОЗИЦІЯ АНТИ-α4β7 АНТИТІЛА
ES2732243T3 (es) 2012-02-16 2019-11-21 Santarus Inc Composiciones farmacéuticas de anticuerpos ANTI-VLA1 (CD49A)
US20190225694A1 (en) 2016-06-28 2019-07-25 Zaklady Farmaceutyczne Polpharma Sa Recombinant production of monoclonal antibodies
EP3541413A2 (en) 2016-11-21 2019-09-25 Polpharma Biologics S.A. Aqueous pharmaceutical formulations
EP3583126B1 (en) * 2017-02-17 2025-08-27 Sanofi Multispecific binding molecules having specificity to dystroglycan and laminin-2
US12043845B2 (en) 2017-06-08 2024-07-23 Polpharma Biologics S.A. Methods of cell culture
JP7457661B2 (ja) 2018-06-04 2024-03-28 バイオジェン・エムエイ・インコーポレイテッド 低減したエフェクター機能を有する抗ｖｌａ－４抗体
US20240301512A1 (en) 2021-01-29 2024-09-12 INSERM (Institut National de la Santé et de la Recherche Médicale) Methods of assessing the risk of developing progressive multifocal leukoencephalopathy in patients treated with vla-4 antagonists

Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
WO1990007861A1 (en) * 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies

Family Cites Families (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
IL95501A (en) * 1989-09-01 1997-04-15 Hutchinson Fred Cancer Res Inhibition by antibodies of lymphocyte adherence to vascular endothelium utilizing an extracellular matrix receptor-ligand interaction, and pharmaceutical compositions containing said antibodies
CA2129637C (en) * 1992-02-12 1999-05-04 Roy R. Lobb Treatment for inflammatory bowel disease
NZ261259A (en) * 1993-01-12 1996-12-20 Biogen Inc Humanised recombinant anti-vla4 antibody and diagnostic compositions and medicaments
AUPP647298A0 (en) 1998-10-13 1998-11-05 Keystone Retaining Wall Systems, Inc. Retaining wall block

Patent Citations (2)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US5225539A (en) * 1986-03-27 1993-07-06 Medical Research Council Recombinant altered antibodies and methods of making altered antibodies
WO1990007861A1 (en) * 1988-12-28 1990-07-26 Protein Design Labs, Inc. CHIMERIC IMMUNOGLOBULINS SPECIFIC FOR p55 TAC PROTEIN OF THE IL-2 RECEPTOR

Non-Patent Citations (1)

* Cited by examiner, † Cited by third party
Title
Nature Vol.356:63-66 (1992. 3. 5) *

Also Published As

Publication number Publication date
AU1696095A (en) 1995-08-08
EP1759709B1 (en) 2013-02-27
HU220799B1 (hu) 2002-05-28
ES2424292T3 (es) 2013-09-30
WO1995019790A1 (en) 1995-07-27
KR970700513A (ko) 1997-02-12
JP2013173738A (ja) 2013-09-05
JP2009235078A (ja) 2009-10-15
FR06C0024I2 (fr) 2009-01-02
NO2006008I1 (no) 2006-08-07
EP0804237A4 (en) 2003-04-16
AU703152B2 (en) 1999-03-18
PL315634A1 (en) 1996-11-25
MX9602971A (es) 1998-01-31
DE69535133D1 (de) 2006-09-07
PT804237E (pt) 2006-10-31
HUT75129A (en) 1997-04-28
NL300238I1 (enExample) 2006-10-02
ATE333895T1 (de) 2006-08-15
NZ279730A (en) 1998-04-27
JP2006045237A (ja) 2006-02-16
HU9602019D0 (en) 1996-09-30
NO963097L (no) 1996-09-24
DK0804237T3 (da) 2006-10-16
DE122006000043I1 (de) 2007-02-15
ES2270425T3 (es) 2007-04-01
EP1759709A1 (en) 2007-03-07
CA2182013C (en) 2007-07-17
NO319867B1 (no) 2005-09-26
NL300238I2 (nl) 2007-05-01
CN1211123C (zh) 2005-07-20
FI117509B (fi) 2006-11-15
FI962958L (fi) 1996-09-24
JP2013165718A (ja) 2013-08-29
LU91271I2 (fr) 2006-10-02
DK1759709T3 (da) 2013-06-10
FR06C0024I1 (enExample) 2006-10-13
NO963097D0 (no) 1996-07-24
JP5487382B2 (ja) 2014-05-07
NO2006008I2 (no) 2009-06-15
EP0804237B1 (en) 2006-07-26
JP4115517B2 (ja) 2008-07-09
NO2017040I1 (no) 2017-08-01
NO2017040I2 (no) 2018-08-28
EP0804237B8 (en) 2006-11-08
CA2182013A1 (en) 1995-07-27
EP0804237A1 (en) 1997-11-05
JPH09508272A (ja) 1997-08-26
FI962958A0 (fi) 1996-07-24
CN1140413A (zh) 1997-01-15
PL181827B1 (pl) 2001-09-28
DE69535133T2 (de) 2008-08-21

Similar Documents

Publication Publication Date Title
JP4115517B2 (ja) 白血球付着分子 ｖｌａ−４に対するヒト化抗体
US5840299A (en) Humanized antibodies against leukocyte adhesion molecule VLA-4
US8246958B2 (en) Methods of inhibiting alpha-4-dependent interactions with VCAM-1 with anti-VLA-4 antibodies
CA2153692C (en) Recombinant anti-vla4 antibody molecules
HK1011031B (en) Recombinant anti-vla4 antibody molecules
HK1112193A (en) A blocking monoclonal antibody to vla-1 and its use for the treatment of inflammatory disorders

Legal Events

Date Code Title Description
PA0105 International application

Patent event date: 19960724

Patent event code: PA01051R01D

Comment text: International Patent Application

PG1501 Laying open of application
A201 Request for examination
AMND Amendment
PA0201 Request for examination

Patent event code: PA02012R01D

Patent event date: 19990525

Comment text: Request for Examination of Application

E902 Notification of reason for refusal
PE0902 Notice of grounds for rejection

Comment text: Notification of reason for refusal

Patent event date: 20010530

Patent event code: PE09021S01D

N231 Notification of change of applicant
PN2301 Change of applicant

Patent event date: 20010817

Comment text: Notification of Change of Applicant

Patent event code: PN23011R01D

AMND Amendment
E601 Decision to refuse application
PE0601 Decision on rejection of patent

Patent event date: 20020430

Comment text: Decision to Refuse Application

Patent event code: PE06012S01D

Patent event date: 20010530

Comment text: Notification of reason for refusal

Patent event code: PE06011S01I

AMND Amendment
J201 Request for trial against refusal decision
PJ0201 Trial against decision of rejection

Patent event date: 20020730

Comment text: Request for Trial against Decision on Refusal

Patent event code: PJ02012R01D

Patent event date: 20020430

Comment text: Decision to Refuse Application

Patent event code: PJ02011S01I

Appeal kind category: Appeal against decision to decline refusal

Decision date: 20020930

Appeal identifier: 2002101002982

Request date: 20020730

PB0901 Examination by re-examination before a trial

Comment text: Amendment to Specification, etc.

Patent event date: 20020730

Patent event code: PB09011R02I

Comment text: Request for Trial against Decision on Refusal

Patent event date: 20020730

Patent event code: PB09011R01I

Comment text: Amendment to Specification, etc.

Patent event date: 20011130

Patent event code: PB09011R02I

Comment text: Amendment to Specification, etc.

Patent event date: 19990525

Patent event code: PB09011R02I

B701 Decision to grant
PB0701 Decision of registration after re-examination before a trial

Patent event date: 20020930

Comment text: Decision to Grant Registration

Patent event code: PB07012S01D

Patent event date: 20020902

Comment text: Transfer of Trial File for Re-examination before a Trial

Patent event code: PB07011S01I

GRNT Written decision to grant
PR0701 Registration of establishment

Comment text: Registration of Establishment

Patent event date: 20021230

Patent event code: PR07011E01D

PR1002 Payment of registration fee

Payment date: 20021231

End annual number: 3

Start annual number: 1

PG1601 Publication of registration
PR1001 Payment of annual fee

Payment date: 20051222

Start annual number: 4

End annual number: 4

PR1001 Payment of annual fee

Payment date: 20061226

Start annual number: 5

End annual number: 5

PR1001 Payment of annual fee

Payment date: 20071224

Start annual number: 6

End annual number: 6

PR1001 Payment of annual fee

Payment date: 20081224

Start annual number: 7

End annual number: 7

PR1001 Payment of annual fee

Payment date: 20091224

Start annual number: 8

End annual number: 8

PR1001 Payment of annual fee

Payment date: 20101208

Start annual number: 9

End annual number: 9

PR1001 Payment of annual fee

Payment date: 20111207

Start annual number: 10

End annual number: 10

PR1001 Payment of annual fee

Payment date: 20121130

Start annual number: 11

End annual number: 11

FPAY Annual fee payment

Payment date: 20131129

Year of fee payment: 12

PR1001 Payment of annual fee

Payment date: 20131129

Start annual number: 12

End annual number: 12

FPAY Annual fee payment

Payment date: 20141210

Year of fee payment: 13

PR1001 Payment of annual fee

Payment date: 20141210

Start annual number: 13

End annual number: 13

EXPY Expiration of term
PC1801 Expiration of term

Termination date: 20150725

Termination category: Expiration of duration